reports
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, TexasEnrolment now open to patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and most deadly primary brain cancer SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only clinical stage cell therapy company on the ASX, is pleased to announce activation of a Phase 1B clinical trial in patients with r...
Chimeric enters strategic manufacturing partnership with WuXi Advanced...
Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies Chimeric Therapeutics will leverage WuXi Advanced Therapies’ (“WuXi ATU”) closed loop CAR T platform and other capabilities to accelerate the clinical development of their CHM 1101 (CLTX CAR T) and CHM 2101 (CDH17 CAR T) programs for glioblastoma and gastrointestinal cancers, respectively MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entere...
- Sean Conroy
Chimeric Therapeutics - Acquiring an exciting new NK cell technology
Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform from Case Western Reserve University for the treatment of cancer. The CORE-NK platform was designed to overcome the hurdles associated with NK cell development and enables the production of large numbers of highly active universal donor NK cells that are active in the body. The company expects to rapidly move to ...
- Sean Conroy
Chimeric Therapeutics - Acquiring an exciting new NK cell technology
Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform from Case Western Reserve University for the treatment of cancer. The CORE-NK platform was designed to overcome the hurdles associated with NK cell development and enables the production of large numbers of highly active universal donor NK cells that are active in the body. The company expects to rapidly move to ...
Chimeric Transforms Portfolio With a Clinically Validated, Off the She...
Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform Chimeric has obtained the exclusive option to license the CORE-NK platform, a Clinically validated, Off the shelf, Robust, Enhanced Natural Killer cell platform from Case Western Reserve University (CWRU)The CORE-NK platform is a transformative platform technology enabling the accelerated development of multiple next generation off the shelf NK and CAR-NK productsThe CORE-NK platform was studied in a phase 1 clinical trial completed in June 2021 in both solid tumours and blood cancer...
- Sean Conroy
Chimeric Therapeutics - Acquiring a promising first-in-class CAR T ass...
Chimeric recently announced that it will be licensing a chimeric antigen receptor t-cell (CAR T) programme targeting cadherin 17 (CDH17) from the University of Pennsylvania. Specific financial terms are undisclosed, but they include an upfront fee, annual maintenance fees, milestones and a royalty (likely single digit, in our view). A CDH17 CAR T may have broad applicability in solid tumours, particularly in neuroendocrine, colorectal, pancreatic and gastric cancers. Importantly, preclinical evi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.